Genotoxic effects of ablative treatment with I-131 determined through the analysis of dicentric chromosomes in peripheral blood lymphocytes. Can it influence the clinical management of patients with differentiated thyroid carcinoma?

Genotoxic effects of ablative treatment with I-131 determined through the analysis of dicentric chromosomes in peripheral blood lymphocytes. Can it influence the clinical management of patients with differentiated thyroid carcinoma?

Study including 61 differentiated thyroid cancer (DTC) patients who received ablative doses of I-131 after total thyroidectomy. Biodosimetry was performed by dicentric chromosomes analysis before and after treatment, determining dicentric yield and blood absorbed dose. An increased yield of dicentri...

Full description

Saved in:
Bibliographic Details
Published in:Radiation physics and chemistry (Oxford, England : 1993) Vol. 223; p. 111927
Main Authors: Fernández Martín, Celia, Alonso Farto, Juan Carlos, Gómez Fernández, Isabel, González Ruiz, Cristina, Lozano Barriuso, Miguel Ángel, Moreno Domene, Mercedes, Orcajo Rincón, Javier, Prieto Rodriguez, María Jesús, Reguera Berenguer, Laura, Sierra Díaz, Fernando, Soza Marañón, Álvaro
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2024
Subjects:
Biodosimetry
Dicentric chromosomes
Internal radiotherapy
Iodine-131
Thyroid cancer
Internal radiotherapy
Biodosimetry
Thyroid cancer
Dicentric chromosomes
Iodine-131
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study including 61 differentiated thyroid cancer (DTC) patients who received ablative doses of I-131 after total thyroidectomy. Biodosimetry was performed by dicentric chromosomes analysis before and after treatment, determining dicentric yield and blood absorbed dose. An increased yield of dicentrics after treatment was demonstrated. With an average administered activity of 4.32 ± 0.879 GBq, the absorbed dose in bone marrow was 0.28 Gy (0.25–0.30 95% CI). These data were compared with the administered I-131 activity and body mass index. Increased genotoxic effects were observed, with a slightly higher dicentric yield rising along I-131 activity. No correlation was found between administered activity and BMI. No significant risk of myelotoxicity due to dose regimens of I-131 intended for ablative purposes in “de novo” treated patients was found among the ranges of activities used in clinical practice. Biodosimetric data was included in patients’ Clinical History, which translates into a more detailed dosimetric report. With this information, physicians can take a more patient-specific approach. Personalized administration would be of special consideration in the event of re-treatments, be it due to recurrent disease or I-131 refractory DTC patients. •Significant increase in dicentric chromosomal aberrations was found.•Myelotoxicity risk induced by therapeutic regimens of I131 was discarded.•No relation between body mass index and estimated dose was demonstrated.•In some cases metastases were identified before clinical signs.•Precaution is advised in the event of retreatments.
ISSN:0969-806X
1879-0895
DOI:10.1016/j.radphyschem.2024.111927